A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2023 Apr 28

PMID 37113469

Authors

Hyun Chul Kim

Sangmi Lee

Siyoung Sung

Eunjin Kim

In-Jin Jang

Jae-Yong Chung

Affiliations

Soon will be listed here.

Abstract

Background: Dapagliflozin formate (DAP-FOR, DA-2811), an ester prodrug of dapagliflozin, was developed to improve the stability and pharmaceutical manufacturing process of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor.

Purpose: This study aimed to evaluate the pharmacokinetics (PKs) and safety of dapagliflozin for DAP-FOR compared to those for dapagliflozin propanediol monohydrate (DAP-PDH, Forxiga) in healthy subjects.

Methods: This was an open-label, randomized, single-dose, two-period, two-sequence crossover study. The subjects received a single dose of DAP-FOR or DAP-PDH 10 mg in each period, with a 7-day washout. Serial blood samples for PK analysis were collected up to 48 hours after a single administration to determine plasma concentrations of DAP-FOR and dapagliflozin. PK parameters were calculated using a non-compartmental method and compared between the two drugs.

Results: In total, 28 subjects completed the study. DAP-FOR plasma concentrations were not detected in all of the blood sampling time points except for one time point in one subject, and the corresponding DAP-FOR plasma concentration in the subject was close to the lower limit of quantification. The mean plasma concentration-time profiles of dapagliflozin were comparable between the two drugs. The geometric mean ratios and its 90% confidence intervals of the maximum plasma concentration and area under the plasma concentration-time curve of dapagliflozin for DAP-FOR to DAP-PDH were within the conventional bioequivalence range of 0.80-1.25. Both drugs were well-tolerated, with a similar incidence of adverse drug reactions.

Conclusion: The rapid conversion of DAP-FOR into dapagliflozin led to the extremely low exposure of DAP-FOR and comparable PK profiles of dapagliflozin between DAP-FOR and DAP-PDH. The safety profiles were also similar between the two drugs. These results suggest that DAP-FOR can be used as an alternative to DAP-PDH.

References

Berry L, Wollenberg L, Zhao Z . Esterase activities in the blood, liver and intestine of several preclinical species and humans. Drug Metab Lett. 2009; 3(2):70-7. DOI: 10.2174/187231209788654081. View

Abet V, Filace F, Recio J, Alvarez-Builla J, Burgos C . Prodrug approach: An overview of recent cases. Eur J Med Chem. 2016; 127:810-827. DOI: 10.1016/j.ejmech.2016.10.061. View

Chen M, Blume H, Beuerle G, Mehta M, Potthast H, Brandt A . Summary report of second EUFEPS/AAPS conference on global harmonization in bioequivalence. Eur J Pharm Sci. 2018; 127:24-28. DOI: 10.1016/j.ejps.2018.10.019. View

. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S125-S143. DOI: 10.2337/dc22-S009. View

Ohura K, Soejima T, Nogata R, Adachi Y, Ninomiya S, Imai T . Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine. J Pharm Sci. 2012; 101(9):3264-74. DOI: 10.1002/jps.23182. View

Martens P, Tits J . Approach to the patient with spontaneous hypoglycemia. Eur J Intern Med. 2014; 25(5):415-21. DOI: 10.1016/j.ejim.2014.02.011. View

Khomitskaya Y, Tikhonova N, Gudkov K, Erofeeva S, Holmes V, Dayton B . Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects. Clin Ther. 2018; 40(4):550-561.e3. DOI: 10.1016/j.clinthera.2018.02.006. View

Yang L, Li H, Li H, Bui A, Chang M, Liu X . Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Ther. 2013; 35(8):1211-1222.e2. DOI: 10.1016/j.clinthera.2013.06.017. View

Zaccardi F, Webb D, Yates T, Davies M . Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J. 2015; 92(1084):63-9. DOI: 10.1136/postgradmedj-2015-133281. View

10.

Najjar A, Karaman R . The prodrug approach in the era of drug design. Expert Opin Drug Deliv. 2018; 16(1):1-5. DOI: 10.1080/17425247.2019.1553954. View

11.

Wu K, Farrelly J . Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: nonclinical Pharm/Tox analysis and the role of comparative toxicology. Toxicology. 2007; 236(1-2):1-6. DOI: 10.1016/j.tox.2007.04.005. View

12.

Shah N, Deeb W, Choksi R, Epstein B . Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2012; 32(1):80-94. DOI: 10.1002/PHAR.1010. View

13.

Chang M, Liu X, Cui D, Liang D, LaCreta F, Griffen S . Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. Clin Ther. 2015; 37(7):1517-28. DOI: 10.1016/j.clinthera.2015.05.004. View

14.

LaCreta F, Griffen S, Liu X, Smith C, Hines C, Volk K . Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets. Int J Pharm. 2016; 511(1):288-295. DOI: 10.1016/j.ijpharm.2016.07.017. View

15.

Kasichayanula S, Liu X, LaCreta F, Griffen S, Boulton D . Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2013; 53(1):17-27. DOI: 10.1007/s40262-013-0104-3. View

16.

Healy A, Worku Z, Kumar D, Madi A . Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. Adv Drug Deliv Rev. 2017; 117:25-46. DOI: 10.1016/j.addr.2017.03.002. View

17.

. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S17-S38. DOI: 10.2337/dc22-S002. View

18.

Melmer A, Laimer M . Treatment Goals in Diabetes. Endocr Dev. 2016; 31:1-27. DOI: 10.1159/000439364. View

19.

Kalra S . Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther. 2014; 5(2):355-66. PMC: 4269649. DOI: 10.1007/s13300-014-0089-4. View

20.

Cho S, Lee J, Yoo Y, Cho M, Sohn S, Lee B . Improved Manufacturability and In Vivo Comparative Pharmacokinetics of Dapagliflozin Cocrystals in Beagle Dogs and Human Volunteers. Pharmaceutics. 2021; 13(1). PMC: 7825777. DOI: 10.3390/pharmaceutics13010070. View